On Heels of Remsima Launch, Celltrion Gears Up For Herceptin Biosimilar Approval In Korea
This article was originally published in PharmAsia News
Following the start of sales of Remsima, a biosimilar of J&J’s Remicade, Celltrion is moving to begin selling its Herceptin biosimilar in Korea this year. It will be Celltron’s second biosimilar on the market.
You may also be interested in...
SEOUL - Seo Jung-Jin, CEO of South Korea's biosimilar front-runner Celltrion, Inc. said his company isn't looking to establish additional sales and distribution partnerships with Big Pharma
Korea's Celltrion SVP Kim Hyoung-Ki On Gearing Up To Launch Biosimilars In Global Markets: An Interview With PharmAsia News
Up until a few years ago, South Korea's biosimilar front-runner Celltrion Inc.'s main business was manufacturing products for others. But the company inked a deal with U.S.-based Hospira in 2009 to collaborate on manufacturing and marketing eight biosimilars. Celltrion has hinted that a bigger deal with Hospira could be in the works, which would provide the Korean company with a global sales network.
SEOUL - Celltrion, Inc. retained upward momentum in its earnings for the second quarter thanks to continued strong shipment of validation batches for biosimilars of Roche's breast cancer agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis drug Remicade (infliximab)